Tumor necrosis factor receptor superfamily member 11B protein (TNFRSF11B) Active Protein | TNFRSF11B active protein

Recombinant Human Tumor necrosis factor receptor superfamily member 11B protein (TNFRSF11B) (Active)

Cat. Num. AAA969417

• Gene Names: TNFRSF11B; OPG; TR1; OCIF; PDB5
• Purity: Greater or equal to 85% purity as determined by SDS-PAGE.
• Synonyms: Tumor necrosis factor receptor superfamily member 11B protein (TNFRSF11B); Recombinant Human Tumor necrosis factor receptor superfamily member 11B protein (TNFRSF11B) (Active); Osteoclastogenesis inhibitory factor; TNFRSF11B active protein

• Host: Yeast
• Purity/Purification: Greater or equal to 85% purity as determined by SDS-PAGE.
• Form/Format: Lyophilized
• Sequence Positions: 22-201aa
• Sequence: ETFPPKYLHY DEETSHQLLC DKCPPGTYLK QHCTAKWKTV CAPCPDHYYT DSWHTSDECL YCSPVCKELQ YVKQECNRTH NRVCECKEGR YLEIEFCLKH RSCPPGFGVV QAGTPERNTV CKRCPDGFFS NETSSKAPCR KHTNCSVFGL LLTQKGNATH DNICSGNSES TQKCGIDVTL+ EPKSSDKTHT CPPCPAPEFE GAPSVFLFPP KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPTPIEKT ISKAKGQPRE PQVYTLPPSR DELTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GK
• Sequence Length: 401

• Species: Homo sapiens (Human)
• Biological Activity: Fully biologically active when compared to standard. The ED50 as determined by neutralizing the stimulation of U937 cells is less than 10 ng/ml, corresponding to a specific activity of > 1.0 × 105 IU/mg in the presence of 10 ng/mL soluble rHuRANKL (sRANKL).
• Endotoxin: Less than 1.0 EU/ug as determined by LAL method.
• Protein Note: Protein will be provided with aseptic processing and endotoxin removal.
• Preparation and Storage: Generally, the shelf life of liquid form is 6 months at -20/-80 degree C. The shelf life of lyophilized form is 12 months at -20/-80 degree C.

Related Product Information for TNFRSF11B active protein

Acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis. {ECO:0000269|PubMed:22664871, ECO:0000269|PubMed:9168977}.

Product Categories/Family for TNFRSF11B active protein

Biological Active Protein; Immunology; Tumor Necrosis Factor

NCBI and Uniprot Product Information

• NCBI GI #: 148743793
• NCBI GeneID: 4982
• NCBI Accession #: NP_002537.3
• NCBI GenBank Nucleotide #: NM_002546.3
• UniProt Accession #: O00300; O60236; Q53FX6; Q9UHP4; B2R9A8
• Molecular Weight: 109.6 kDa
• NCBI Official Full Name: tumor necrosis factor receptor superfamily member 11B
• NCBI Official Synonym Full Names: TNF receptor superfamily member 11b
• NCBI Official Symbol: TNFRSF11B
• NCBI Official Synonym Symbols: OPG; TR1; OCIF; PDB5
• NCBI Protein Information: tumor necrosis factor receptor superfamily member 11B
• UniProt Protein Name: Tumor necrosis factor receptor superfamily member 11B
• Protein Family: Tumor necrosis factor receptor superfamily
• UniProt Gene Name: TNFRSF11B
• UniProt Synonym Gene Names: OCIF; OPG

NCBI Description

The protein encoded by this gene is a member of the TNF-receptor superfamily. This protein is an osteoblast-secreted decoy receptor that functions as a negative regulator of bone resorption. This protein specifically binds to its ligand, osteoprotegerin ligand, both of which are key extracellular regulators of osteoclast development. Studies of the mouse counterpart also suggest that this protein and its ligand play a role in lymph-node organogenesis and vascular calcification. Alternatively spliced transcript variants of this gene have been reported, but their full length nature has not been determined. [provided by RefSeq, Jul 2008]

Uniprot Description

TNFRSF11B: Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis. Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD); also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast- mediated skeletal resorption, the disease can be fatal.

Protein type: Inhibitor; Secreted; Secreted, signal peptide

Chromosomal Location of Human Ortholog: 8q24.12

Cellular Component: extracellular region; extracellular space; integral to plasma membrane; plasma membrane

Molecular Function: cytokine activity; receptor activity; tumor necrosis factor receptor activity

Biological Process: immune response; inflammatory response; regulation of apoptosis; regulation of cell proliferation; response to lipopolysaccharide; signal transduction; skeletal development; tumor necrosis factor-mediated signaling pathway

Disease: Paget Disease, Juvenile